Kenya - English - Pharmacy and Poisons Board

bilthoven biologicals b.v antonie van leeuwenhoeklaan 9-13, bilthoven, 3721 - inactivated poliomyelitis virus type 1… - suspension for injection - inactivated poliomyelitis virus type 1 -40… - viral vaccines: poliomyelitis vaccines

Uganda - English - National Drug Authority

serum institute of india pvt ltd - polio virus (sabin) - oral liquid ordinary liquids - type - i ?106.0 ccid50 type - iii ?105.8 ccid50

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - polio virus type 1 29 dagu (mahoney by parallel line method (equiv to 40 dagu by sigmoid method)); polio virus type 2 7 dagu (mef1 by parallel line method (equiv to 8 dagu by sigmoid method)); polio virus type 3 26 dagu (saukett by parallel line method (equiv to 32 dagu by sigmoid method)) - suspension for injection - active: polio virus type 1 29 dagu (mahoney by parallel line method (equiv to 40 dagu by sigmoid method)) polio virus type 2 7 dagu (mef1 by parallel line method (equiv to 8 dagu by sigmoid method)) polio virus type 3 26 dagu (saukett by parallel line method (equiv to 32 dagu by sigmoid method)) excipient: formaldehyde phenoxyethanol polysorbate 80 water for injection - ipol is indicated for active immunisation of infants, children and adults for the prevention of poliomyelitis. recommendations for the use of live and inactivated poliovirus vaccines are described in the national immunisation guidelines. 1. general recommendations. it is recommended that all infants, unimmunised children and adolescents not previously immunised be vaccinated routinely against paralytic poliomyelitis. ipol should be offered to patients who have refused opv, or in whom opv is contraindicated. 2. ipol is also indicated for: · the primary vaccination of immunocompromised individuals of all ages (see precautions), and household contacts of such individuals (when vaccination is indicated) · unvaccinated or inadequately vaccinated (*) adults, particularly if at increased risk of exposure to live poliovirus, including: · travellers to areas or countries where poliomyelitis is epidemic or endemic; · laboratory workers handling specimens which may contain polioviruses; · health care workers in close contact with patients who may be excreting polioviruses. (*) such as those who had not completed a primary series of vaccination or not received a booster dose since infancy.

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - poliomyelitis virus (sabin strain) type min 1000000 tcid50/0.5 ml - suspension - min 1000000 tcid50/0.5 ml

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - virus polio type 1, strain lsc, 2ab; virus polio type 3, strain leon 12a, 1b - suspension - virus polio type 1, strain lsc, 2ab ≥10⁶·˚ccid₅₀; virus polio type 3, strain leon 12a, 1b ≥10⁵·⁸ccid₅₀

Canada - English - Health Canada

sanofi pasteur limited - inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney - solution - 8unit; 32unit; 40unit - inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1 8unit; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett 32unit; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney 40unit - vaccines

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - polio virus type 1 40 dagu (mahoney); polio virus type 2 8 dagu (mef 1); polio virus type 3 32 dagu (saukett) - suspension for injection - 40dagu/8dagu/32dagu - active: polio virus type 1 40 dagu (mahoney) polio virus type 2 8 dagu (mef 1) polio virus type 3 32 dagu (saukett) excipient: formaldehyde phenoxyethanol polysorbate 80 water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - polio virus type 1 40 dagu; polio virus type 2 8 dagu; polio virus type 3 32 dagu - solution for injection - active: polio virus type 1 40 dagu polio virus type 2 8 dagu polio virus type 3 32 dagu excipient: albumin formaldehyde phenoxyethanol

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - polio virus type 1 300000 tcid50; polio virus type 2 100000 tcid50; polio virus type 3 300000 tcid50 - oral suspension - 0.5 ml - active: polio virus type 1 300000 tcid50 polio virus type 2 100000 tcid50 polio virus type 3 300000 tcid50 excipient: albumin magnesium chloride hexahydrate phenolsulfonphthalein

Canada - English - Health Canada

sanofi pasteur limited - filamentous haemagglutinin; pertussis toxoid; pertactin; tetanus toxoid; fimbriae types 2 and 3 (fim); poliovirus type 1 mahoney (inactivated); poliovirus type 2 mef1 (inactivated); poliovirus type 3 saukett (inactivated); diphtheria toxoid - suspension - 5mcg; 2.5mcg; 3mcg; 5lf; 5mcg; 29unit; 7unit; 26unit; 2lf - filamentous haemagglutinin 5mcg; pertussis toxoid 2.5mcg; pertactin 3mcg; tetanus toxoid 5lf; fimbriae types 2 and 3 (fim) 5mcg; poliovirus type 1 mahoney (inactivated) 29unit; poliovirus type 2 mef1 (inactivated) 7unit; poliovirus type 3 saukett (inactivated) 26unit; diphtheria toxoid 2lf - vaccines